Protagonist Therapeutics Closes Worldwide Rusfertide License and Collaboration Agreement with Takeda; Protagonist Will Receive The $300M Upfront Payment Associated With The Transaction In The Second Quarter Of 2024
Author: Benzinga Newsdesk | March 18, 2024 07:12am